Menu
GeneBe

GNE

glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase

Basic information

Region (hg38): 9:36214440-36277042

Previous symbols: [ "IBM2" ]

Links

ENSG00000159921NCBI:10020OMIM:603824HGNC:23657Uniprot:Q9Y223AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • GNE myopathy (Definitive), mode of inheritance: AR
  • sialuria (Strong), mode of inheritance: AD
  • GNE myopathy (Strong), mode of inheritance: AR
  • sialuria (Supportive), mode of inheritance: AD
  • GNE myopathy (Supportive), mode of inheritance: AD
  • platelet-type bleeding disorder 19 (Supportive), mode of inheritance: AR
  • sialuria (Limited), mode of inheritance: AD
  • GNE myopathy (Strong), mode of inheritance: AR
  • sialuria (Strong), mode of inheritance: AD
  • macrothrombocytopenia, isolated (Moderate), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Sialuria, French type ; Nonaka myopathy; Inclusion body myopathy, autosomal recessiveAD/ARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingBiochemical; Gastrointestinal; Musculoskeletal; Neurologic7252518; 2443758; 2808337; 1779656; 8439453; 10330343; 11528398; 11486897; 11326336; 12473780; 11916006; 12473753; 12177386; 12473769; 16372135; 17718674; 20059379; 20175955; 20300792; 20301343; 20301439; 20346669; 21131200; 21708040; 22196754; 22507750; 22883483; 23127962; 24685570; 24796702

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the GNE gene.

  • GNE myopathy (299 variants)
  • not provided (290 variants)
  • GNE myopathy;Sialuria (280 variants)
  • Sialuria;GNE myopathy (272 variants)
  • Sialuria (112 variants)
  • Inclusion Body Myopathy, Recessive (61 variants)
  • not specified (36 variants)
  • Inborn genetic diseases (8 variants)
  • GNE-related condition (3 variants)
  • Thrombocytopenia (2 variants)
  • Inclusion body myositis;GNE myopathy (1 variants)
  • See cases (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the GNE gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
3
clinvar
153
clinvar
1
clinvar
157
missense
12
clinvar
27
clinvar
246
clinvar
1
clinvar
286
nonsense
10
clinvar
23
clinvar
33
start loss
2
clinvar
2
frameshift
24
clinvar
26
clinvar
50
inframe indel
1
clinvar
8
clinvar
9
splice donor/acceptor (+/-2bp)
5
clinvar
7
clinvar
12
splice region
1
20
31
52
non coding
2
clinvar
60
clinvar
80
clinvar
35
clinvar
177
Total 53 84 319 234 36

Highest pathogenic variant AF is 0.0000921

Variants in GNE

This is a list of pathogenic ClinVar variants found in the GNE region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
9-36214458-ATT-A Sialuria • GNE myopathy • Inclusion Body Myopathy, Recessive Uncertain significance (Jun 14, 2016)366794
9-36214488-A-G GNE myopathy • Inclusion Body Myopathy, Recessive • Sialuria Uncertain significance (Jan 12, 2018)366795
9-36214518-A-G GNE myopathy • Inclusion Body Myopathy, Recessive • Sialuria Uncertain significance (Jan 13, 2018)366796
9-36214576-C-T Sialuria • GNE myopathy • Inclusion Body Myopathy, Recessive Benign/Likely benign (Jan 13, 2018)366797
9-36214599-A-G Inclusion Body Myopathy, Recessive • Sialuria • GNE myopathy Uncertain significance (Jan 13, 2018)366798
9-36214656-A-G Sialuria • GNE myopathy Uncertain significance (Jan 12, 2018)915006
9-36214686-C-T Inclusion Body Myopathy, Recessive • Sialuria • GNE myopathy Uncertain significance (Jan 13, 2018)366799
9-36214789-T-C Sialuria • Inclusion Body Myopathy, Recessive • GNE myopathy Likely benign (Apr 27, 2017)366800
9-36214815-C-T GNE myopathy • Sialuria Uncertain significance (Jan 13, 2018)913051
9-36214828-C-T GNE myopathy • Sialuria Uncertain significance (Jan 13, 2018)913052
9-36214912-G-T Sialuria • GNE myopathy Uncertain significance (Jan 13, 2018)913053
9-36214917-T-C Inclusion Body Myopathy, Recessive • GNE myopathy • Sialuria Uncertain significance (Jan 12, 2018)366801
9-36214934-T-C GNE myopathy • Sialuria Uncertain significance (Jan 13, 2018)913416
9-36214950-A-T Sialuria • Inclusion Body Myopathy, Recessive • GNE myopathy Conflicting classifications of pathogenicity (Jan 13, 2018)366802
9-36214955-C-G Inclusion Body Myopathy, Recessive • GNE myopathy • Sialuria Uncertain significance (Jun 14, 2016)366803
9-36214974-G-A Sialuria • Inclusion Body Myopathy, Recessive • GNE myopathy Benign (May 13, 2021)366804
9-36215096-G-A Sialuria • GNE myopathy • Inclusion Body Myopathy, Recessive Likely benign (Apr 27, 2017)366805
9-36215120-T-A Sialuria • GNE myopathy Uncertain significance (Jan 13, 2018)914530
9-36215154-G-C GNE myopathy • Inclusion Body Myopathy, Recessive • Sialuria Benign/Likely benign (Jan 13, 2018)366806
9-36215168-C-CA Sialuria • GNE myopathy • Inclusion Body Myopathy, Recessive Benign (Jun 14, 2016)366807
9-36215180-A-T GNE myopathy • Sialuria Uncertain significance (Jan 15, 2018)915058
9-36215209-C-G Inclusion Body Myopathy, Recessive • Sialuria • GNE myopathy Benign (Jan 12, 2018)366808
9-36215309-G-A Sialuria • Inclusion Body Myopathy, Recessive • GNE myopathy Benign/Likely benign (Jan 13, 2018)366809
9-36215511-G-A GNE myopathy • Sialuria Uncertain significance (Jan 13, 2018)912328
9-36215539-C-G GNE myopathy • Inclusion Body Myopathy, Recessive • Sialuria Benign (Jan 12, 2018)366810

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
GNEprotein_codingprotein_codingENST00000396594 1262616
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
2.48e-160.05991256910571257480.000227
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense2.592714200.6450.00002334958
Missense in Polyphen90168.570.533891949
Synonymous1.591281530.8370.000008461505
Loss of Function0.8282732.10.8420.00000194367

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0003910.000391
Ashkenazi Jewish0.000.00
East Asian0.0001630.000163
Finnish0.00004620.0000462
European (Non-Finnish)0.0003630.000352
Middle Eastern0.0001630.000163
South Asian0.0001310.000131
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Regulates and initiates biosynthesis of N- acetylneuraminic acid (NeuAc), a precursor of sialic acids. Plays an essential role in early development (By similarity). Required for normal sialylation in hematopoietic cells. Sialylation is implicated in cell adhesion, signal transduction, tumorigenicity and metastatic behavior of malignant cells. {ECO:0000250, ECO:0000269|PubMed:10334995}.;
Disease
DISEASE: Sialuria (SIALURIA) [MIM:269921]: In sialuria, free sialic acid accumulates in the cytoplasm and gram quantities of neuraminic acid are secreted in the urine. The metabolic defect involves lack of feedback inhibition of UDP-GlcNAc 2-epimerase by CMP-Neu5Ac, resulting in constitutive overproduction of free Neu5Ac. Clinical features include variable degrees of developmental delay, coarse facial features and hepatomegaly. Sialuria inheritance is autosomal dominant. {ECO:0000269|PubMed:10330343, ECO:0000269|PubMed:10356312, ECO:0000269|PubMed:11326336, ECO:0000269|PubMed:2808337}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Nonaka myopathy (NM) [MIM:605820]: Autosomal recessive muscular disorder, allelic to inclusion body myopathy 2. It is characterized by weakness of the anterior compartment of the lower limbs with onset in early adulthood, and sparing of the quadriceps muscles. As the inclusion body myopathy, NM is histologically characterized by the presence of numerous rimmed vacuoles without inflammatory changes in muscle specimens. {ECO:0000269|PubMed:11528398, ECO:0000269|PubMed:11916006, ECO:0000269|PubMed:12177386, ECO:0000269|PubMed:12325084, ECO:0000269|PubMed:12409274, ECO:0000269|PubMed:12473753, ECO:0000269|PubMed:12473769, ECO:0000269|PubMed:12473780, ECO:0000269|PubMed:12497639, ECO:0000269|PubMed:12811782, ECO:0000269|PubMed:12913203, ECO:0000269|PubMed:15146476}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Amino sugar and nucleotide sugar metabolism - Homo sapiens (human);Sialuria or French Type Sialuria;Sialuria or French Type Sialuria;Amino Sugar Metabolism;G(M2)-Gangliosidosis: Variant B, Tay-sachs disease;Tay-Sachs Disease;Salla Disease/Infantile Sialic Acid Storage Disease;Aminosugars metabolism;Post-translational protein modification;Metabolism of proteins;CMP-<i>N</i>-acetylneuraminate biosynthesis I (eukaryotes);Sialic acid metabolism;Synthesis of substrates in N-glycan biosythesis;Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein;Asparagine N-linked glycosylation (Consensus)

Recessive Scores

pRec
0.257

Intolerance Scores

loftool
0.0436
rvis_EVS
-0.03
rvis_percentile_EVS
51.92

Haploinsufficiency Scores

pHI
0.436
hipred
N
hipred_score
0.362
ghis
0.523

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.971

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Gne
Phenotype
growth/size/body region phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype;

Zebrafish Information Network

Gene name
gne
Affected structure
fast muscle cell
Phenotype tag
abnormal
Phenotype quality
disorganized

Gene ontology

Biological process
N-acetylglucosamine biosynthetic process;UDP-N-acetylglucosamine metabolic process;N-acetylneuraminate metabolic process;cell adhesion;carbohydrate phosphorylation
Cellular component
cytoplasm;cytosol
Molecular function
hydrolase activity, hydrolyzing O-glycosyl compounds;protein binding;ATP binding;UDP-N-acetylglucosamine 2-epimerase activity;N-acylmannosamine kinase activity;metal ion binding